ORDER A KIT
FoundationACT is Foundation Medicine’s comprehensive
liquid biopsy, which may provide more treatment options for your patients with the simplicity of a blood draw.
 
Interrogates the 62 most clinically-relevant cancer genes in solid tumors
Validated to identify all 4 alteration types
Superior sensitivity and specificity

What is a Liquid Biopsy?

The FoundationACT liquid biopsy looks at free-floating DNA—specifically the segment of circulating tumor DNA, or ctDNA—that sheds into the blood from a patient’s tumor. By analyzing ctDNA in a peripheral blood sample, we may be able to detect which altered genes are driving a patient’s disease, without using an invasive tissue biopsy.

When should I use a liquid biopsy?

  • When tissue is unobtainable for any reason
  • When you suspect progression of disease, or presence of resistance mutations
  • When you do not have time to wait for a biopsy
  • To assist in therapy selection
  • To probe for evidence of tumor burden in the blood
  • To provide complementary information to prior or future tissue testing

See FAQs below for more

In which tumor types is a liquid biopsy most appropriate?

While research is still emerging on this, there is evidence that lung, gastrointestinal, and breast cancers, among others, have high concordance between blood and tissue based testing, indicating that ctDNA can be an appropriate surrogate for tissue. 

See FAQs below for more

 

 

Select Publications and Posters

 

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

Journal of Thoracic Oncology, 2017

Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM

Clinical Lung Cancer, 2016 December

Allen JM, Schrock AB, Erlich RL, Miller VA, Stephens PJ, Ross JS, Ou SI, Ali SM, Vafai D.



CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays

Journal of Thoracic Oncology, 2017 February

Wang V, Bivona T, Ali SM, Schrock AB, Miller VA

 

Presented at the European Society for Medical Oncology Congress 2016 
 
Presented at the World Conference for Lung Cancer 2016 
 
Presented at the 2017 Gastrointestinal Cancers Symposium (American Society of Clinical Oncology)
 
FAQs
WHEN SHOULD I USE A LIQUID BIOPSY?

(Continued from above) Liquid biopsies are valuable for patients without a recent tissue biopsy. FoundationACT is often ordered when tissue is unavailable or when an oncologist suspects progression of disease in patients on targeted therapy. Clinical consensus on issues differentiating a liquid biopsy and tissue biopsy (ie, which tumor types are most appropriate for one versus the other, or the proper time to perform a liquid biopsy) is still emerging, but the field views these modalities to be highly complementary.

WHAT GENES ARE REPORTED WITH FOUNDATIONACT?
The 62 most actionable and clinically relevant genes in solid tumors according to data. See the full list here.
WHAT DO I NEED TO SEND TO GET FOUNDATIONACT TESTING?

We require two 10mL tubes of blood for FoundationACT testing. You can request a kit here and use this kit and its inserts to obtain the sample and ship safely back to Cambridge. For more information on how to order, please contact our client services department, or review our guidelines for acquiring a sample.

WHAT IS THE TURN-AROUND TIME?

Typically, you will receive results 14 days from receipt of the blood sample.

WHAT INFORMATION DOES THE REPORT PROVIDE?

The FoundationACT report includes the mutations found in the patient’s blood sample, and the associated targeted therapies and clinical trials. You can see an example of a report here. The FoundationACT report can incorporate results from prior FoundationOne or FoundationACT testing to provide an integrated view of your patient’s tumor evolution.

IN WHICH TUMOR TYPES IS A LIQUID BIOPSY APPROPRIATE?

(Continued from above) Many other factors affect presence of ctDNA in the blood, beyond tumor type. Burden of disease and response to therapy are two such factors, among others, which are still being evaluated. Foundation Medicine is committed to advancing the field’s understanding of the role for tissue and blood-based assays.

IS FOUNDATIONACT COVERED BY MY PATIENT'S INSURANCE?

Foundation Medicine’s policy is to file claims and pursue any necessary appeals on your behalf for the testing services completed. Our testing services are covered by a number of national and regional health plans, and we are an in-network provider with an increasing number of health plans.

OBTAINING A BLOOD DRAW FOR MY PATIENT IS STILL DIFFICULT FOR ME. ARE THERE ALTERNATIVES?

Foundation Medicine does offer Mobile Phlebotomy for certain patients/practices. Learn more about this program here.